These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 32809875)

  • 41. Safety of Contemporary Heart Failure Therapy in Patients with Continuous-Flow Left Ventricular Assist Devices.
    Schnettler JK; Roehrich L; Just IA; Pergantis P; Stein J; Mueller M; Mulzer J; Knierim J; Falk V; Potapov FE; Schoenrath F
    J Card Fail; 2021 Dec; 27(12):1328-1336. PubMed ID: 34157393
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aptamer-Based Proteomic Platform Identifies Novel Protein Predictors of Incident Heart Failure and Echocardiographic Traits.
    Nayor M; Short MI; Rasheed H; Lin H; Jonasson C; Yang Q; Hveem K; Felix JF; Morrison AC; Wild PS; Morley MP; Cappola TP; Benson MD; ; ; Ngo D; Sinha S; Keyes MJ; Shen D; Wang TJ; Larson MG; Brumpton BM; Gerszten RE; Omland T; Vasan RS
    Circ Heart Fail; 2020 May; 13(5):e006749. PubMed ID: 32408813
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach.
    Hoes MF; Tromp J; Ouwerkerk W; Bomer N; Oberdorf-Maass SU; Samani NJ; Ng LL; Lang CC; van der Harst P; Hillege H; Anker SD; Metra M; van Veldhuisen DJ; Voors AA; van der Meer P
    Eur J Heart Fail; 2020 Nov; 22(11):2102-2111. PubMed ID: 31797504
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prioritizing Candidates of Post-Myocardial Infarction Heart Failure Using Plasma Proteomics and Single-Cell Transcriptomics.
    Chan MY; Efthymios M; Tan SH; Pickering JW; Troughton R; Pemberton C; Ho HH; Prabath JF; Drum CL; Ling LH; Soo WM; Chai SC; Fong A; Oon YY; Loh JP; Lee CH; Foo RSY; Ackers-Johnson MA; Pilbrow A; Richards AM
    Circulation; 2020 Oct; 142(15):1408-1421. PubMed ID: 32885678
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Proteomic profiling for detection of early-stage heart failure in the community.
    Cauwenberghs N; Sabovčik F; Magnus A; Haddad F; Kuznetsova T
    ESC Heart Fail; 2021 Aug; 8(4):2928-2939. PubMed ID: 34050710
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure.
    Ferreira JP; Verdonschot J; Collier T; Wang P; Pizard A; Bär C; Björkman J; Boccanelli A; Butler J; Clark A; Cleland JG; Delles C; Diez J; Girerd N; González A; Hazebroek M; Huby AC; Jukema W; Latini R; Leenders J; Levy D; Mebazaa A; Mischak H; Pinet F; Rossignol P; Sattar N; Sever P; Staessen JA; Thum T; Vodovar N; Zhang ZY; Heymans S; Zannad F
    Circ Heart Fail; 2019 May; 12(5):e005897. PubMed ID: 31104495
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transient Receptor Potential Channels, Natriuretic Peptides, and Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure.
    Ding K; Gui Y; Hou X; Ye L; Wang L
    Front Cardiovasc Med; 2022; 9():904881. PubMed ID: 35722101
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Biomarkers in Heart Failure: Current and Future].
    Kozhevnikova MV; Belenkov YN
    Kardiologiia; 2021 May; 61(5):4-16. PubMed ID: 34112070
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Toward a New Paradigm for Targeted Natriuretic Peptide Enhancement in Heart Failure.
    Gidlöf O
    Front Physiol; 2021; 12():650124. PubMed ID: 34721050
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure.
    Sama IE; Woolley RJ; Nauta JF; Romaine SPR; Tromp J; Ter Maaten JM; van der Meer P; Lam CSP; Samani NJ; Ng LL; Metra M; Dickstein K; Anker SD; Zannad F; Lang CC; Cleland JGF; van Veldhuisen DJ; Hillege HL; Voors AA
    Eur J Heart Fail; 2020 May; 22(5):821-833. PubMed ID: 32243695
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of Biopsy Proven Liver Fibrosis on Patients Undergoing Evaluation and Treatment for Advanced Heart Failure Surgical Therapies.
    Goyal A; Dalia T; Ranka S; Sauer AJ; Hu J; Cernik C; Nuqali A; Chandler J; Parimi N; Dennis K; Majmundar M; Tayeb T; Haglund J; Shah Z; Vidic A; Gupta B; Haglund NA
    Am J Cardiol; 2023 May; 194():46-55. PubMed ID: 36947946
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets.
    Cao TH; Jones DJL; Voors AA; Quinn PA; Sandhu JK; Chan DCS; Parry HM; Mohan M; Mordi IR; Sama IE; Anker SD; Cleland JG; Dickstein K; Filippatos G; Hillege HL; Metra M; Ponikowski P; Samani NJ; Van Veldhuisen DJ; Zannad F; Lang CC; Ng LL
    Eur J Heart Fail; 2020 Jan; 22(1):70-80. PubMed ID: 31692186
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multiplexed MRM-Based Proteomics Identified Multiple Biomarkers of Disease Severity in Human Heart Failure.
    Brioschi M; Gianazza E; Agostoni P; Zoanni B; Mallia A; Banfi C
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467687
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multi-omics analyses identify molecular signatures with prognostic values in different heart failure aetiologies.
    Aboumsallem JP; Shi C; De Wit S; Markousis-Mavrogenis G; Bracun V; Eijgenraam TR; Hoes MF; Meijers WC; Screever EM; Schouten ME; Voors AA; Silljé HHW; De Boer RA
    J Mol Cell Cardiol; 2023 Feb; 175():13-28. PubMed ID: 36493852
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Heart failure in obesity: insights from proteomics in patients treated with or without weight-loss surgery.
    Karason K; Girerd N; Andersson-Asssarsson J; Duarte K; Taube M; Svensson PA; Huby AC; Peltonen M; Carlsson LM; Zannad F
    Int J Obes (Lond); 2022 Dec; 46(12):2088-2094. PubMed ID: 35945262
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Angiotensin Receptor-Neprilysin Inhibition (ARNI) Therapy and Reverse Remodeling in Heart Failure With Reduced Ejection Fraction.
    Drazner MH
    JAMA; 2019 Sep; 322(11):1051-1053. PubMed ID: 31475298
    [No Abstract]   [Full Text] [Related]  

  • 57. Insights into therapeutic targets and biomarkers using integrated multi-'omics' approaches for dilated and ischemic cardiomyopathies.
    Kanapeckaitė A; Burokienė N
    Integr Biol (Camb); 2021 May; 13(5):121-137. PubMed ID: 33969404
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Scenarios in precision medicine: proteomics in heart failure.
    Gentile P; Palazzini M; Garascia A; Oliva F
    Eur Heart J Suppl; 2022 Nov; 24(Suppl I):I111-I113. PubMed ID: 36380813
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Will introduction of ARNI reduce the need of device therapy in heart failure with reduced ejection fraction?
    Kaur N; Pruthvi CR; Rohit M
    Egypt Heart J; 2021 Mar; 73(1):26. PubMed ID: 33725186
    [No Abstract]   [Full Text] [Related]  

  • 60. Common- and rare-variant genetic architecture of heart failure across the allele frequency spectrum.
    Lee DSM; Cardone KM; Zhang DY; Abramowitz S; DePaolo JS; Aragam KG; Biddinger K; Conery M; Dilitikas O; Hoffman-Andrews L; Judy RL; Khan A; Kulo I; Puckelwartz MJ; Reza N; Satterfield BA; Singhal P; ; Arany ZP; Cappola TP; Carruth E; Day SM; Do R; Haggarty CM; Joseph J; McNally E; Nadkarni G; Owens AT; Rader DJ; Ritchie MD; Sun Y; Voight BF; Levin MG; Damrauer SM
    medRxiv; 2023 Oct; ():. PubMed ID: 37503172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.